A Multicenter, Randomized, Double-Blind Study Comparing The Efficacy And Safety Of Aflibercept Versus Placebo Administered Every 3 Weeks In Patients Treated With Docetaxel / Prednisone For Metastatic Androgen-Independent Prostate Cancer
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Aflibercept (Primary) ; Docetaxel; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms VENICE
- Sponsors Sanofi
- 07 Jun 2022 Results (n=2028) from 4 randomized phase 3 trials (NCT00273338, NCT00988208, NCT00617669, and NCT00519285) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 18 May 2020 Results (n=1577) of Ascent2, Mainsail and Venice trials, inverse correlation between obesity and mortality in patients, presented at the 115th Annual Meeting of the American Urological Association.